...
首页> 外文期刊>Haematologica >Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement | Haematologica
【24h】

Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement | Haematologica

机译:携带bcl-2 / Jh重排的淋巴瘤中Bcl-6 p53突变血液学

获取原文
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND AND OBJECTIVES: The t(14;18)(q32;q21) chromosomal translocation is the hallmark of follicular lymphomas (FL). The translocation induces the overexpression of the Bcl-2 protein and prolongs the survival of clonogenic cells. Tumor cells may acquire additional molecular alterations that may be associated with histologic progression or with chemo-resistance. DESIGN AND METHODS: We analyzed the distribution and association of bcl-6 and p53 mutations in 55 consecutive bcl-2/Jh+ lymphoma samples derived from 43 patients obtained at the time of diagnosis and, in 5 of these patients, during follow-up. A total of 29 bcl-6 point mutations were detected in seventeen patients (40%) associated with major or minor breakpoints of the bcl-2/Jh fusion gene. In seven cases a p53 mutation was detected. Three cases corresponded to FL with the minor breakpoint in the bcl-2 gene and these patients had a favorable clinical evolution, whereas the 4 patients with p53 mutations and the major breakpoint had a bad clinical outcome with morphologic transformation to high-grade lymphoma in three cases. The sequential analysis of 5 patients showed a different timing in the acquisition of mutations: one patient showed bcl-6 and p53 mutations at diagnosis, another patient showed bcl-6 mutations at diagnosis and acquired a p53 mutation later whereas the third patient had a p53 mutation before the appearance of the bcl-6 mutation. RESULTS: We did not find significant differences in survival between patients with FL who showed exclusively bcl-6 mutations and those without bcl-6 mutations, but those patients with a high International Progostic Index score and p53 mutations showed the lowest overall survival (p = 0.002). INTERPRETATION AND CONCLUSIONS: These findings suggest that bcl-2/Jh lymphomas show molecular heterogeneity and that bcl-6 and p53 mutations may be acquired during the evolution of such lymphomas. Bcl-6 mutations, by themselves, do not seem to be associated with a bad prognosis. Rearrangements at the minor bcl-2 locus may have a different molecular evolution.
机译:背景与目的:t(14; 18)(q32; q21)染色体易位是滤泡性淋巴瘤(FL)的标志。易位诱导Bcl-2蛋白的过表达并延长克隆细胞的存活。肿瘤细胞可能会获得其他与组织学进展或抗化学性相关的分子改变。设计和方法:我们分析了55例连续bcl-2 / Jh +淋巴瘤样本中bcl-6和p53突变的分布和关联,这些样本来自诊断时的43例患者,其中5例在随访期间。在与bcl-2 / Jh融合基因的主要或次要断裂点相关的十七名患者中(40%)检测到总共29个bcl-6点突变。在七个案例中,检测到p53突变。 3例对应于FL,bcl-2基因具有较小的断裂点,并且这些患者的临床进展良好,而4例具有p53突变和主要断裂点的患者中有3例发生了形态学转变为高级别淋巴瘤的不良临床预后案件。对5例患者进行的顺序分析显示,突变的获取时间有所不同:一名患者在诊断时显示bcl-6和p53突变,另一名患者在诊断时显示bcl-6和p53突变,后来又获得了p53突变,而第三名患者的p53突变bcl-6突变出现之前发生突变。结果:我们没有发现仅显示bcl-6突变的FL患者和没有bcl-6突变的FL患者的生存率有显着差异,但是国际Progostic Index得分高且p53突变的FL患者的总生存率最低(p = 0.002)。解释和结论:这些发现表明bcl-2 / Jh淋巴瘤表现出分子异质性,并且在此类淋巴瘤的进化过程中可能会获得bcl-6和p53突变。 Bcl-6突变本身似乎与不良预后无关。次要bcl-2基因座的重排可能具有不同的分子进化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号